European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) - Business Wire

European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)  Business Wire

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for ...



Comments

Popular posts from this blog

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic ...

Mechanism and clinical progression of solid tumors bone marrow metastasis

Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions